← Alle Unternehmen
Über das Unternehmen
Shaping the Future of Cancer Treatment and Metabolic Diseases through First-in-class Antibodies and Bifunctional Proteins focusing on Metabolic Checkpoints, reprogramming the immune microenvironment to conquer hard-to-treat cancer and immune-related diseases.